BioNTech In Another China ADC Deal, This Time With Medilink

HER3-Targeting Asset

 
• By Dexter Jie Yan
  
Generate a summary of this article
Listen to this article
Beta

Medilink’s ADC platform, which addresses the antibody endocytosis process, has received its first endorsement from a major international partner in the form of BioNTech.

unique
BioNTech picks Medilink’s differentiated TMALIN ADC platform in HER3-targeting ADC deal • Source: Shutterstock

Following two separate deals with Duality Biologics, BioNTech SE has inked another antibody-drug conjugate (ADC) collaboration with another Chinese firm, Suzhou Medilink Therapeutics Ltd., in a deal worth up to more than $1bn. At the center of the agreement is YL202, a HER3-targeting candidate, Medilink announced on 12 October.

Key Takeaways

  • In exchange for global rights to YL202, BioNTech will pay Medilink $70m upfront, as well as development, regulatory and commercial milestone payments that could take total deal value to $1bn-plus.

The collaboration marks Medilink's first major alliance with a leading international partner, which has put in the spotlight the Chinese...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from China

  • Iran Deal In Place, But API Prices Stay Elevated And Pharma Supply Chains Face A Slow Recovery

    A framework to end the Iran war is in place but fractured supply chains can’t recover overnight. Data from India suggests solvent prices have generally cooled from April peaks, but API costs stay elevated or even climbed in June for some products.

  • Embracing China’s Brave New Pharmaceutical World!

     
    • By Ellon Xu, Philip Leung, and Grace Shieh

    Already one of the world’s largest pharmaceutical markets, China has tremendous growth potential, but significant policy and market changes are rocking the basis of competition. Multinational biopharma corporations cannot succeed in this new environment unless they fundamentally reinvent their business models to adapt to sweeping change.

  • Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]

    Pipelines in bioconjugates continue to develop, from ADCs to XDCs, with radionuclide drug conjugates (RDCs) and antibody-oligonucleotide conjugates (AOCs) leading the expansion.

  • Fosun ALK/ROS1 Inhibitor Shows 1L Promise In Advanced NSCLC

    Interim results from the Phase III REMARK study presented at WCLC showed the Chinese company’s second-generation ALK/ROS1 inhibitor met its primary endpoint as a first-line therapy in ALK-positive advanced NSCLC.

More from Focus On Asia